Top Markets
#1 Black Phoenix Black Phoenix +197.93%
#2 Islamic Coin Islamic Coin +157.91%
#3 Glidr Glidr +84.34%
#4 Gold Park Gold Park +48.15%
#5 BasedHype BasedHype +39.22%
#6 Acurast Acurast +26.47%
#7 Cryptopia Cryptopia +21.79%
#8 Quantum Resistant Ledger Quantum Resistant Ledger +20.90%
#9 Akedo Akedo +19.20%
#10 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +16.57%
Coin of the day
Black Phoenix Black Phoenix
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
InNexus Biotechnology, Inc. InNexus Biotechnology, Inc.

InNexus Biotechnology, Inc.

IXSBF
Classifica tra le azioni #41697
InNexus Biotechnology, Inc. is a development-stage company dedicated to... InNexus Biotechnology, Inc. is a development-stage company dedicated to advancing and commercializing monoclonal antibodies. Its efforts are underpinned by its proprietary Dynamic Cross Linking (DXL) technology. This DXL platform is designed to boost the therapeutic efficacy of conventional monoclonal antibody treatments by strengthening their binding to target antigens, amplifying their effector functions, and endowing them with novel properties. InNexus's development portfolio features several investigational therapies: DXL625: A monoclonal antibody currently in late-stage pre-clinical development, engineered for superior binding kinetics and enhanced effector functions, intended for treating B-cell non-Hodgkin's lymphoma (NHL). DXLr120: A recombinant DXL anti-CD20 antibody also being developed for B-cell NHL. DXL702: A monoclonal antibody targeting metastatic breast cancer. DXL1218: An agent designed to target the epidermal growth factor receptor (EGFR), an antigen frequently overexpressed in metastatic colorectal cancer and squamous cell carcinomas of the head and neck. The company also maintains strategic partnerships with XERIS Pharmaceuticals, Genhelix, Evogenix, Affimed, and Corixa. InNexus Biotechnology, Inc. is based in Vancouver, Canada.
Prezzo delle azioni
$0.0001
Ultima sincronizzazione: 2025-11-07
Capitalizzazione di mercato
$12.63K
Variazione (1 giorno)
0.00%
Variazione (1 anno)
0.00%
Paese
CA
Scambia InNexus Biotechnology, Inc. (IXSBF)

Categoria

Healthcare
Rapporto P/S per InNexus Biotechnology, Inc. (IXSBF)
Rapporto P/S al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di InNexus Biotechnology, Inc., il rapporto P/S attuale (TTM) è 0. Alla fine del 2026, era pari a 0.
Storico del rapporto P/S per InNexus Biotechnology, Inc. da 2026 a 2026
Rapporto P/S alla fine di ogni anno
Anno Rapporto P/S Cambia
Non abbastanza dati per le date fornite.
Rapporto P/S per aziende simili o concorrenti
Azienda Rapporto P/S Differenza del rapporto P/S Il paese
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
10.30 -
US
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB
SOBI.ST
- -
SE
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
- -
FR
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A.
REC.MI
- -
IT
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated
CORT.US
14.90 -
US